Advertisement

Ads Placeholder
Loading...

Deinove SA

ALDEI.PAEURONEXT
Healthcare
Biotechnology
0.03
0.00(0.00%)
U.S. Market opens in 55h 53m

Deinove SA Fundamental Analysis

Deinove SA (ALDEI.PA) shows moderate financial fundamentals with a PE ratio of -0.11, profit margin of -19.05%, and ROE of 60.55%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

ROE60.55%
Cash Position507.06%
PEG Ratio-0.00

Areas of Concern

Operating Margin-19.98%
We analyze ALDEI.PA's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -1721.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-1721.7/100

We analyze ALDEI.PA's fundamental strength across five key dimensions:

Efficiency Score

Weak

ALDEI.PA struggles to generate sufficient returns from assets.

ROA > 10%
-74.55%

Valuation Score

Excellent

ALDEI.PA trades at attractive valuation levels.

PE < 25
-0.11
PEG Ratio < 2
-0.00

Growth Score

Weak

ALDEI.PA faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

ALDEI.PA maintains a strong and stable balance sheet.

Debt/Equity < 1
-0.49
Current Ratio > 1
1.36

Profitability Score

Weak

ALDEI.PA struggles to sustain strong margins.

ROE > 15%
60.55%
Net Margin ≥ 15%
-19.05%
Positive Free Cash Flow
No

Key Financial Metrics

Is ALDEI.PA Expensive or Cheap?

P/E Ratio

ALDEI.PA trades at -0.11 times earnings. This suggests potential undervaluation.

-0.11

PEG Ratio

When adjusting for growth, ALDEI.PA's PEG of -0.00 indicates potential undervaluation.

-0.00

Price to Book

The market values Deinove SA at -0.06 times its book value. This may indicate undervaluation.

-0.06

EV/EBITDA

Enterprise value stands at 0.20 times EBITDA. This is generally considered low.

0.20

How Well Does ALDEI.PA Make Money?

Net Profit Margin

For every $100 in sales, Deinove SA keeps $-19.05 as profit after all expenses.

-19.05%

Operating Margin

Core operations generate -19.98 in profit for every $100 in revenue, before interest and taxes.

-19.98%

ROE

Management delivers $60.55 in profit for every $100 of shareholder equity.

60.55%

ROA

Deinove SA generates $-74.55 in profit for every $100 in assets, demonstrating efficient asset deployment.

-74.55%

Following the Money - Real Cash Generation

Operating Cash Flow

Deinove SA generates limited operating cash flow of $-9.00M, signaling weaker underlying cash strength.

$-9.00M

Free Cash Flow

Deinove SA generates weak or negative free cash flow of $-9.40M, restricting financial flexibility.

$-9.40M

FCF Per Share

Each share generates $-0.22 in free cash annually.

$-0.22

FCF Yield

ALDEI.PA converts -5.53% of its market value into free cash.

-5.53%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-0.11

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.00

vs 25 benchmark

P/B Ratio

Price to book value ratio

-0.06

vs 25 benchmark

P/S Ratio

Price to sales ratio

3.09

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-0.49

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.36

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.61

vs 25 benchmark

ROA

Return on assets percentage

-0.75

vs 25 benchmark

ROCE

Return on capital employed

-1.45

vs 25 benchmark

How ALDEI.PA Stacks Against Its Sector Peers

MetricALDEI.PA ValueSector AveragePerformance
P/E Ratio-0.1128.45 Better (Cheaper)
ROE60.55%763.00% Weak
Net Margin-1904.90%-45265.00% (disorted) Weak
Debt/Equity-0.490.34 Strong (Low Leverage)
Current Ratio1.362795.60 Neutral
ROA-74.55%-16588.00% (disorted) Weak

ALDEI.PA outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Deinove SA's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ